Endocrine Abstracts

Background: Empagliflozin is a sodium-glucose-cotransporter-2 that improves cardiovascular risk and weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit in PCOS.Methods: A randomised, open-label study in 40 overweight and obese women with PCOS treated with either empagliflozin 25 mg or metformin 1500mg daily for 12 weeks....